# Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients

> **NCT03205267** · PHASE2 · UNKNOWN · sponsor: **University of Bonn** · enrollment: 127 (estimated)

## Conditions studied

- Chronic Myelogenous Leukaemia

## Interventions

- **DRUG:** Bosulif

## Key facts

- **NCT ID:** NCT03205267
- **Lead sponsor:** University of Bonn
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 127 (ESTIMATED)
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03205267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03205267, "Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03205267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*